Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.12 -				0.00 -	0.37 319,329.86%	0.24 36.24%
cash per share	0.39 -	0.85 115.12%	3.15 272.83%	8.59 172.30%	3.32 61.40%	3.93 18.43%	0.00 99.94%
company equity multiplier	-0.76 -	-0.59 22.49%	-0.98 67.17%	1.42 244.23%	1.72 21.58%	1.88 8.79%	2.64 40.82%
days of inventory outstanding
days of payables outstanding
days of sales outstanding						25.45 -	50.83 99.75%
dividend yield
ebit per revenue	-6.59 -				-4.53 -	-0.46 89.84%	-2.00 335.26%
ebt per ebit	1.03 -	1.06 3.49%	1.01 4.77%	1.03 1.37%	0.88 13.82%	1.06 19.78%	0.95 10.04%
effective tax rate	0.03 -	0.00 82.65%	-0.07 1,659.82%	19.90 28,268.87%	36.24 82.12%	-0.01 100.02%	0.00 110.12%
enterprise value multiple	-28.93 -	-13.28 54.10%	-7.34 44.71%	-2.93K 39,843.31%	-2.29K 21.84%	-6.81 99.70%	-2.34K 34,267.49%
fixed asset turnover	1.73 -				0.00 -	2.79 431,130.33%	1.59 43.20%
free cash flow per share	-0.58 -	-1.09 89.79%	-1.75 60.03%	-3.62 106.71%	-1.69 53.29%	-0.43 74.76%	-0.00 99.75%
gross profit margin	1 -				1 -	1 0%	1 0%
interest coverage	-35.25 -	-23.38 33.67%	-24.07 2.97%	-36.09 49.94%	-42.11 16.67%	-9.41 77.65%	14.94 258.71%
inventory turnover
long term debt to capitalization	-0.34 -	-0.33 3.90%	-0.21 36.02%	0.17 181.29%	0.26 50.91%	0.31 17.90%	0.43 41.58%
net income per ebt	0.97 -	1.00 2.22%	1.07 7.55%	-18.90 1,865.08%	-35.24 86.47%	1.01 102.86%	1.00 0.76%
net profit margin	-6.59 -				140.98 -	-0.49 100.35%	-1.91 288.55%
operating cash flow per share	-0.57 -	-1.06 85.22%	-1.62 53.17%	-3.15 94.27%	-1.65 47.66%	-0.37 77.42%	-0.00 99.73%
operating profit margin	-6.59 -				-4.53 -	-0.46 89.84%	-2.00 335.26%
payables turnover
pretax profit margin	-6.76 -				-4.00 -	-0.49 87.83%	-1.91 291.55%
price fair value	-18.18 -	-7.19 60.46%	-4.08 43.26%	1.51 136.95%	2.71 79.99%	2.03 25.07%	2.92K 143,641.89%
receivables turnover						14.34 -	7.18 49.94%
return on assets	-0.77 -	-0.98 27.40%	-0.63 35.96%	0.01 101.05%	0.02 147.70%	-0.18 1,212.42%	-0.45 147.74%
return on capital employed	-1.08 -	-1.31 21.12%	-0.68 47.76%	-0.00 99.95%	-0.00 68.85%	-0.20 32,050.61%	-0.64 217.76%
return on equity	0.59 -	0.58 1.26%	0.62 7.05%	0.01 98.49%	0.03 201.14%	-0.34 1,310.18%	-1.19 248.87%
total debt to capitalization	-0.41 -	-0.33 18.69%	-0.24 26.90%	0.18 176.26%	0.28 52.47%	0.32 14.09%	0.45 40.64%

COM:POSEIDA

Poseida Therapeutics, Inc.

Last Close

2.71

22/11 21:00

Market Cap

288.93M

Beta: -

Volume Today

364.94K

Avg: -

Preview